Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic–uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding of eculizumab pharmacokinetics and subsequent individual dose adjustment could reduce this cost. We measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatault, Philippe, Brachet, Guillaume, Ternant, David, Degenne, Danielle, Récipon, Guillaume, Barbet, Christelle, Gyan, Emmanuel, Gouilleux-Gruart, Valérie, Bordes, Cécile, Farrell, Alexandra, Halimi, Jean Michel, Watier, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966484/
https://www.ncbi.nlm.nih.gov/pubmed/26337866
http://dx.doi.org/10.1080/19420862.2015.1086049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966484/
https://www.ncbi.nlm.nih.gov/pubmed/26337866
http://dx.doi.org/10.1080/19420862.2015.1086049

Ejemplares similares